Physician profile

David Kaufman

Otolaryngology · New York, NY

NPI 1285601203

$796.17

in general payments reported to CMS, 2019-2025

9 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$178.64

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Baxter Healthcare $235.00 2020
Dilon Technologies, INC. $159.84 2023 Hemoblast Bellows
Fisher & Paykel Healthcare INC $149.53 2019-2022
Dompe US, INC. $126.40 2022
Allergan, INC. $49.68 2021
Medtronic USA, INC. $31.64 2019
Abbvie INC. $25.28 2022
Supernus Pharmaceuticals, INC. $18.80 2023 Qelbree

1 company reported research payments only; those appear in the research section below.

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

David Kaufman

$796.17

in general payments reported 2019-2025

Years
2019-2023
Top company
Baxter Healthcare

https://glasscript.com/doctor/627928/david-kaufman

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.